Celcuity (NASDAQ:CELC) Rating Increased to Strong-Buy at Wolfe Research

Wolfe Research upgraded shares of Celcuity (NASDAQ:CELC) to a strong-buy rating in a report published on Monday,Zacks.com reports.

CELC has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a “neutral” rating and issued a $94.00 price objective (up from $77.00) on shares of Celcuity in a research report on Monday. Craig Hallum increased their target price on Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Guggenheim initiated coverage on Celcuity in a report on Monday, September 22nd. They issued a “buy” rating for the company. Finally, Needham & Company LLC set a $95.00 price target on Celcuity in a report on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $97.00.

Celcuity Stock Up 2.8%

NASDAQ:CELC traded up $2.66 during trading hours on Monday, reaching $96.89. 275,667 shares of the company traded hands, compared to its average volume of 735,638. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. The business’s 50-day moving average price is $63.59 and its two-hundred day moving average price is $38.66. Celcuity has a 1 year low of $7.57 and a 1 year high of $98.43. The stock has a market capitalization of $4.48 billion, a P/E ratio of -26.42 and a beta of 0.72.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.13. Analysts predict that Celcuity will post -2.62 earnings per share for the current year.

Institutional Trading of Celcuity

Several institutional investors have recently made changes to their positions in the business. Harvest Investment Services LLC bought a new stake in Celcuity during the 3rd quarter valued at approximately $1,427,000. Voloridge Investment Management LLC purchased a new stake in Celcuity during the 3rd quarter valued at approximately $9,439,000. Verition Fund Management LLC bought a new stake in shares of Celcuity during the third quarter valued at approximately $4,012,000. Scientech Research LLC purchased a new position in shares of Celcuity in the third quarter worth $777,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Celcuity during the third quarter worth $329,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.